News
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Novo Nordisk shares surged after Eli Lilly's weight-loss pill underperformed expectations in trial results. This setback is ...
The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...
Novo Nordisk today announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded drugs ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...
Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback